Clinical trials · Virginia
Cardiomyopathies clinical trials in Virginia
We’re tracking 17 recruiting cardiomyopathies studies with a site in Virginia — including Phase 2, Phase 2/Phase 3, Phase 3 and Phase 4 studies, each written for real people, not researchers.
Recruiting studies in Virginia
- NCT07052903RecruitingPhase 3
RNA therapy for ATTR amyloidosis with heart involvement
This trial tests an experimental RNA therapy (nucresiran) for people with transthyretin amyloidosis that causes heart problems (cardiomyopathy). It aims to lower the abnormal protein buildup to help heart function.
Charlottesville, VirginiaAges 18–85 - NCT05180773RecruitingPhase 4
Bromocriptine for new postpartum heart weakness
This trial studies whether bromocriptine improves health outcomes in people recently diagnosed with peripartum cardiomyopathy (a weakened heart during late pregnancy or soon after delivery). You may be asked about timing after childbirth, heart strength tests, and whether you plan to keep breastfeeding.
Charlottesville, VirginiaAges 18 years+ - NCT06563895RecruitingPhase 3
Testing acoramidis to prevent ATTR amyloidosis in gene carriers
This trial tests a daily pill called acoramidis to see if it can prevent ATTR amyloidosis in people who carry a gene mutation but have no symptoms yet. It aims to stop the disease before it starts.
Falls Church, VirginiaAges 18–75 - NCT05489705Recruiting
Real-world registry for mavacamten and other obstructive HCM treatments
This study collects real-world information about people with obstructive hypertrophic cardiomyopathy (HCM) who are being treated with mavacamten or other standard medicines. It aims to understand patient characteristics, treatment choices over time, and long-term outcomes.
Charlottesville, VirginiaAges 18 years+ - NCT06128629RecruitingPhase 3
A study of NTLA-2001 for transthyretin amyloidosis with heart problems
This study tests a new treatment, NTLA-2001, for people with a type of heart disease called transthyretin amyloidosis with cardiomyopathy. It aims to see if the medicine can help improve heart function and quality of life.
Richmond, VirginiaAges 18–90 - NCT07023614RecruitingPhase 2
Study of Ninerafaxstat for Non-Obstructive Hypertrophic Cardiomyopathy
This trial tests an investigational drug (ninerafaxstat) for people with a specific type of thickened heart muscle called non-obstructive hypertrophic cardiomyopathy. The goal is to see if the drug can improve symptoms and exercise ability.
Charlottesville, VirginiaAges 18 years+ - NCT07674758Recruiting
Understanding heart risk in Duchenne and Becker muscular dystrophy
This study looks at heart health in people with Duchenne or Becker muscular dystrophy to find better ways to predict and track heart problems. The goal is to improve future treatment trials.
Richmond, VirginiaAges Any age - NCT05667493Enrolling by invitationPhase 3
Long-term safety follow-up for eplontersen in ATTR heart disease
This is a long-term study to check the safety of eplontersen over time in adults with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM). It is mainly for people who already took the study medication before, or who joined an earlier related study and are doing well.
Richmond, VirginiaAges 18 years+ - NCT07207811RecruitingPhase 3
Study of coramitug for heart failure from ATTR amyloidosis
This study tests an investigational medicine called coramitug in people with heart failure caused by ATTR amyloidosis, a condition where abnormal protein builds up in the heart. The goal is to see if it can slow or improve heart function.
Falls Church, VirginiaAges 18 years+ - NCT05650658Recruiting
Compare two heart pacing options in people with weak heart function
This trial compares two types of “left-side” heart pacing to see which one works better in people with weak heart pumping. It may help guide the best pacing choice for improving heart function and symptoms.
Newport News, VirginiaAges 18 years+ - NCT06023186Recruiting
Effect of mavacamten on heart blood flow in HCM
This study tests whether the drug mavacamten (Camzyos) improves blood flow in the heart's small vessels for people with obstructive hypertrophic cardiomyopathy. You will take mavacamten as prescribed and have a PET/CT scan to measure your heart's blood flow reserve.
Charlottesville, VirginiaAges 18–85 - NCT06964464RecruitingPhase 4
Comparing two heart failure medications in ICD patients
This trial compares two beta-blocker medications, carvedilol and metoprolol succinate, to see which one works better for people with heart failure who have an implantable cardioverter defibrillator (ICD). If you are currently taking metoprolol succinate, you may be able to switch to carvedilol and help researchers find the best treatment.
Richmond, VirginiaAges 18 years+ - NCT07054073Recruiting
HCMR Re-Imaging: MRI follow-up for HCM patients
This study uses MRI scans to re-examine people with hypertrophic cardiomyopathy (a thickening of the heart muscle) who were part of the original HCMR study. It compares different types of HCM to learn more over time.
Charlottesville, VirginiaAges 18–65 - NCT00733590Recruiting
Study after ICD generator replacement for heart attack patients
This study follows people who had a prior heart attack and later received a replacement ICD (a device that helps prevent sudden dangerous heart rhythms). It is observational, meaning it mainly looks at outcomes and device-related information rather than testing a new drug.
Richmond, VirginiaAges 18–85 - NCT01790152Recruiting
Dexrazoxane study to monitor heart damage in cancer survivors
This study tests dexrazoxane (DRZ) to see how it affects blood and heart-related “biomarkers,” or measurable signs of heart damage, after cancer treatment. It mainly targets survivors who may be at risk for cardiomyopathy (heart muscle weakness) or related heart failure.
Richmond, VirginiaAges Any age - NCT04848506Enrolling by invitationPhase 2/Phase 3
Long-term safety follow-up with aficamten for adults with HCM
This study checks how safe and well-tolerated aficamten is over the long run in adults with hypertrophic cardiomyopathy (HCM). You may be eligible if you finished a prior Cytokinetics aficamten study and your heart pumping strength is in the required range.
Charlottesville, VirginiaAges 18–85 - NCT04520347Enrolling by invitation
Registry for heart rhythm ablation in VT or PVC
This study is a “registry,” meaning it collects information about people undergoing a procedure to treat abnormal heart rhythms like ventricular tachycardia (VT) or premature ventricular contractions (PVCs). It may help researchers better understand which patients benefit from the procedure and how it is done over time.
Charlottesville, VirginiaAges Any age
Cardiomyopathies trials by city in Virginia
Where these studies are running in Virginia
Institutions with a site for the recruiting cardiomyopathies studies listed above.
- Virginia Commonwealth University · 10 studies
- Inova Fairfax Medical Campus · 4 studies
- University of Virginia · 4 studies
- University of Virginia Health System · 2 studies
- Carilion Clinic
- Children's Hospital of Richmond at VCU
- Clinical Trial Site
- Imbria Investigational Site
What taking part in a cardiomyopathies study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Cardiomyopathies trials in other states
Common questions
- Are there cardiomyopathies clinical trials in Virginia?
- Yes. We're currently tracking 17 recruiting cardiomyopathies studies with a site in Virginia, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a cardiomyopathies study in Virginia?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Virginia to take part?
- Not necessarily. These studies have a site in Virginia, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a cardiomyopathies trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New cardiomyopathies studies open in Virginia regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.